Literature DB >> 20600933

Tamoxifen dose response and conditional cell marking: is there control?

Debra Ellisor1, Mark Zervas.   

Abstract

Conditional marking and gene inactivation experiments are valuable approaches used to understand developmental and molecular mechanisms. CreER(T) is a fundamental component in recombinase-based conditional strategies and is used to gain temporal control subsequent to tamoxifen administration. We tested the hypothesis that tamoxifen dose linearly correlates with recombination efficiency in vivo. Wnt1-CreER(T) and tamoxifen administration were used to mark progenitors that contributed to the trigeminal ganglia. We executed a dose response study to determine the number of neurons that had undergone recombination in response to tamoxifen administered at doses ranging from 50 to 500 mg/kg. Our findings show a substantial variability in the amount of recombination within and between dose groups with no clear correlation between tamoxifen dose and the number of marked cells. This is the first study that we are aware of in which cell counts, robust quantitative data, and statistical analyses were performed on sections obtained from embryos marked in response to a wide range of tamoxifen dose in vivo. We provide an important quantitative and statistical framework for designing CreER(T)-based experiments and choosing tamoxifen dosing paradigms. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600933     DOI: 10.1016/j.mcn.2010.06.004

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  12 in total

1.  Molecular organization and timing of Wnt1 expression define cohorts of midbrain dopamine neuron progenitors in vivo.

Authors:  Ashly Brown; Jason T Machan; Lindsay Hayes; Mark Zervas
Journal:  J Comp Neurol       Date:  2011-10-15       Impact factor: 3.215

Review 2.  Alternative approaches to modeling hereditary dystonias.

Authors:  Rachel Fremont; Kamran Khodakhah
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

3.  Wnt1 expression temporally allocates upper rhombic lip progenitors and defines their terminal cell fate in the cerebellum.

Authors:  Nellwyn Hagan; Mark Zervas
Journal:  Mol Cell Neurosci       Date:  2011-12-06       Impact factor: 4.314

4.  Fate mapping melanoma persister cells through regression and into recurrent disease in adult zebrafish.

Authors:  Jana Travnickova; Sarah Muise; Sonia Wojciechowska; Alessandro Brombin; Zhiqiang Zeng; Adelaide I J Young; Cameron Wyatt; E Elizabeth Patton
Journal:  Dis Model Mech       Date:  2022-09-16       Impact factor: 5.732

5.  Evaluation of a library of loxP variants with a wide range of recombination efficiencies by Cre.

Authors:  Yuji Yamauchi; Hidenori Matsukura; Keisuke Motone; Mitsuyoshi Ueda; Wataru Aoki
Journal:  PLoS One       Date:  2022-10-21       Impact factor: 3.752

6.  The lineage contribution and role of Gbx2 in spinal cord development.

Authors:  Brian Luu; Debra Ellisor; Mark Zervas
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

7.  The Temporal Contribution of the Gbx2 Lineage to Cerebellar Neurons.

Authors:  Nellwyn Hagan; Juliana Guarente; Debra Ellisor; Mark Zervas
Journal:  Front Neuroanat       Date:  2017-07-21       Impact factor: 3.856

8.  Temporal Expression of Wnt1 Defines the Competency State and Terminal Identity of Progenitors in the Developing Cochlear Nucleus and Inferior Colliculus.

Authors:  Stephen Brown; Mark Zervas
Journal:  Front Neuroanat       Date:  2017-08-22       Impact factor: 3.856

9.  Refined protocols of tamoxifen injection for inducible DNA recombination in mouse astroglia.

Authors:  Hannah M Jahn; Carmen V Kasakow; Andreas Helfer; Julian Michely; Alexei Verkhratsky; Hans H Maurer; Anja Scheller; Frank Kirchhoff
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379

10.  The kinetics of ER fusion protein activation in vivo.

Authors:  C H Wilson; I Gamper; A Perfetto; J Auw; T D Littlewood; G I Evan
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.